MannKind has filed a patent for a method of treating hyperglycemia and/or diabetes in patients with type 2 diabetes mellitus. The method involves administering a formulation containing a GLP-1 molecule and a diketopiperazine through pulmonary inhalation using a dry powder inhalation system. The patent also claims an inhalable dry powder pharmaceutical composition containing a neuroactive agent and 3,6-di(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine or its pharmaceutically acceptable salt. GlobalData’s report on MannKind gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on MannKind, Smart inhalers was a key innovation area identified from patents. MannKind's grant share as of September 2023 was 53%. Grant share is based on the ratio of number of grants to total number of patents.
A patent filed for an inhalable dry powder pharmaceutical composition
A recently filed patent (Publication Number: US20230293436A1) describes an inhalable dry powder pharmaceutical composition for the treatment of diseases or disorders. The composition includes a neuroactive agent and 3,6-di(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine, or a pharmaceutically acceptable salt thereof.
The neuroactive agent in the composition can be an immunomodulating agent, an inflammatory mediator, or a synthetic organic compound. The composition also includes microparticles with a diameter of less than 10 µm, with a significant portion (about 35% to about 75%) having an aerodynamic diameter of less than 5.8 µm. These microparticles are characterized by assemblages of crystalline plates with irregular surfaces.
In addition to the active ingredients, the composition may contain one or more pharmaceutically acceptable carriers and/or excipients.
The patent also describes a method of treating a disease or disorder by administering the inhalable dry powder pharmaceutical composition to a subject. The method follows the same principles as the composition, including the use of a neuroactive agent, microparticles with specific size characteristics, and the inclusion of carriers and/or excipients.
Overall, this patent presents a novel inhalable dry powder pharmaceutical composition that combines a neuroactive agent with 3,6-di(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine. The composition's unique characteristics, such as the size and shape of the microparticles, make it suitable for the treatment of various diseases and disorders. The method of administration described in the patent provides a potential therapeutic approach for delivering the composition to patients.
To know more about GlobalData’s detailed insights on MannKind, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
